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Background:  The inflammatory cytokine interleukin-6 (IL-6) has been previously associated with acute decompensated heart failure 
(ADHF). Prior observation has suggested that IL-6 may identify ADHF patients who respond better to nesiritide than nitroglycerin (Circ 
Heart Fail. 2011; 4:450-5.).
methods:  We analyzed the association between baseline IL-6 in ADHF and mortality at 30 and 180 days, using a cohort of 881 patients 
from the ASCEND-HF trial (nesiritide vs placebo). Plasma IL-6 (Singulex) values were measured at the time of hospitalization (baseline), 
48-72 hours and 30 days.
results:  Univariable analysis showed that IL-6 was associated with mortality at 30 days (IL-6 at baseline: HR 3.2, 95% CI 1.2-8.8; 48-
72 hours: HR 6.6, 95% CI 1.5-29) and 180 days (IL-6 at baseline: HR 1.7, 95% CI 1.1-2.8; 48-72 hours: 2.63, 95% CI 1.5-4.6; 30 days: 
HR 3.3, 95% CI 1.6-7.0). Change in IL-6 from baseline to 30 days was also associated with 180-day mortality (HR 2.2, 95% CI 1.1-4.6). 
However, multivariable analysis adjusting for age, log(BUN), sodium, baseline hypotension, and baseline dyspnea at rest showed that 
neither IL-6 nor change in IL-6 independently predicted mortality at 30 or 180 days (all p>0.05). Treatment with nesiritide vs placebo was 
found to have no significant effect on IL-6 levels at measured time points (Figure, all p>0.05).
conclusion:  While IL-6 is associated with mortality in ADHF, it does not independently predict mortality, contradicting previously published 
work in smaller cohorts.
 
